Drug Profile
6-Aminonicotinamide
Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Nicotinamide adenine dinucleotide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Aug 1996 Preclinical development for Cancer in USA (Unknown route)